About IXINITY®
- Adolescent and Adult Patients
- Younger Patients
- Safety
- Product Features
- About Ixinity
Discover IXINITY for the treatment of hemophilia B.
What is IXINITY?
IXINITY® [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Hemophilia B is an inherited bleeding disorder that prevents clotting. For children and adults, your healthcare provider may give you IXINITY for on-demand treatment and control of bleeding episodes, when you have surgery, or for routine prophylaxis to prevent bleeding episodes.
IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.
IXINITY allows you to define your IXperience.
No longer are people with hemophilia B defined by their condition—they’re defined by their abilities and their passions.
IXINITY is a blood-clotting medicine for hemophilia B. IXINITY has an average incremental recovery of 98% in adolescent and adult patients who are 12 years of age or older, and 79% in children under 12 years of age.1 Higher recovery may allow lower doses.
IXINITY also has a terminal half-life of 24 hours in adolescent and adult patients who are 12 years of age or older, and 16.3 hours in children under 12 years of age.1 This allows for peak factor levels when you need them.
A different IXperience for people with hemophilia B.
John Taylor’s Hemophilia B Journey
The founder of the Coalition for Hemophilia B and the father of a son with hemophilia B shares his inspiring story of hope.
Medexus Pharma
Making connections that matter.
At Medexus, we take pride in our patient-first philosophy that focuses on improving people’s lives through a personalized approach that helps us understand people’s needs and a passion for creating solutions that align with their goals.
Learn more about Medexus Pharma.
Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Medexus Pharma, Inc.; March 2024.